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In this issue of Cell Reports, Almendro et al. report one of the first comprehensive studies on the
intratumor heterogeneity of cell phenotypes and genotypes before and after chemotherapy in
breast cancer. These data challenge the concept of genetic population bottlenecks and suggest
that cellular phenotypes play an important role in developing resistance to therapy.Intratumor heterogeneity was originally
reported as early as the late 1800s by
pathologists and gained further evidence
by cytologists in the late 1900s with the
development of chromosome staining
techniques. In the last decade, there has
been an overwhelming amount of data
on genetic intratumor heterogeneity,
largely because of the advent of next-
generation sequencing methods. How-
ever, although many studies have
reported that intratumor heterogeneity
exists in many human cancers, few have
ventured into the questions of why it ex-
ists and whether it plays an important
role in tumor progression. Clonal diversity
may be critically important when tumor
cells encounter selective pressures,
including the immune system, hypoxia,
nutrient deprivation, geographic isolation,
and, perhaps strongest of all, chemo-
therapy (Burrell et al., 2013; Merlo et al.,
2006). Although several studies have
investigated intratumor heterogeneity
prior to chemotherapy and often report
that increased diversity correlates with
resistance (Chen et al., 2012; Mroz et al.,
2013), few have analyzed the diversity of
tumor cells in posttreatment samples. In
this issue of Cell Reports, Almendro
et al. (2014) have investigated the role of
intratumor heterogeneity in response to
neoadjuvant therapy in breast cancer
patients by examining both pre- and
posttreatment samples.
An important distinction in studying
intratumor heterogeneity is the difference
between genotypic diversity and pheno-
typic diversity. Genomic mutations may
not necessarily result in phenotypicchanges in cells, and, conversely, varia-
tions in phenotypes do not necessarily
imply different mutations. In their previous
work leading up to the present study,
Almendro et al. (2014) developed an
approach called iFISH to track both
phenotypic and genotypic diversity by
combing fluorescence in situ hybridiza-
tion with immunocytochemistry (Park
et al., 2010). The advantage of this
approach is that it can determine the
genotype and phenotype of thousands
of single cells and determine their spatial
organizations in situ. Using this approach,
they investigated differences in intratumor
heterogeneity in three major subtypes of
breast cancer (luminal A, Her2, and
basal-like) and reported that the basal-
like tumors showed the highest levels of
genetic diversity and a strong bias toward
mesenchymal phenotypes.
In the present study, Almendro et al.
(2014) selected a cohort of 47 breast
cancer patients that span the four major
subtypes of breast cancer (luminal A,
luminal B, Her2, and basal-like). They
collected longitudinal tumor samples
before neoadjuvant treatment (using
anthracyclins or taxol derivatives) and
60–300 days after treatment. To track
phenotypes, they stained cells with anti-
bodies in order to distinguish between
differentiated (CD24+) and mesenychmal
(CD44+) phenotypes. To measure geno-
types, they analyzed copy-number states
using FISH probes for 8q24.3, 10p13,
16p13.3, and 20q13.31. In total, they
analyzed 21,236 single cancer cells and
used statistical methods from ecology to
calculate diversity indexes, including theCell Reports 6,Shannon and Simpson indices. From
this data, they compared changes in the
diversity indices before and after neoadju-
vant therapy.
Challenging a population of tumor cells
with a drug could have several outcomes
on the diversity of the population. The
therapy could completely eradicate the
tumor cell population (Figure 1A) or lead
to a population bottleneck followed by
the reconstitution of the tumor mass by
the resistant clones (Figure 1B). Alterna-
tively, the drug could have no effect on
the diversity of the tumor cell population
(Figure 1C). The current paradigm holds
that tumor cells are diverse populations
that harbor resistance mutations in rare
clones (Merlo et al., 2006; Nowell, 1976).
When challenged with therapy, this model
predicts that the majority of the tumor
mass will be eliminated; however, over
time, the mass will slowly be repopulated
by resistant clones. However, the data
reported by Almendro et al. (2014) are
inconsistent with this model, instead
showing that genetic diversity did not
change after chemotherapy (Figure 1C).
These data may be explained if most of
the tumor cells, regardless of genotype,
are resistant to the therapy. Alternatively,
the tumor cell populations may have
undergone a population bottleneck for a
brief period of time but then quickly repo-
pulated the tumor mass and its diversity
over the time period (60–300 days)
that occurred before the posttreatment
samples were collected.
In contrast to genetic diversity,
Almendro et al. (2014) did observed signif-
icant changes in phenotypic diversity. InFebruary 13, 2014 ª2014 The Authors 417
Figure 1. Models of Genetic and Phenotypic Diversity in Response to Therapy
(A) Genetically homogenous population with complete response.
(B) Genetic population bottleneck and selection of CD44+ phenotypes.
(C) No change in genetic diversity after therapy, but phenotypic selection of CD44+ cells.most of the patients, the tumor cells
shifted from a differentiated pheno-
type (CD24+/CD44) to a mesenchymal
phenotype (CD24/CD44+) after therapy.
This pattern occurred in all of the sub-
types except for the Her2 tumors. The
change in phenotypes was also accom-
panied by a decrease in overall cell prolif-
eration (Ki67 staining), suggesting that the
chemotherapy may have eliminated most
of the rapidly dividing cells while leaving
the slowly proliferating cells intact. These
data suggest that cell phenotypes play a
critical role in developing resistance to
neoadjuvant therapy in breast cancer.
Almendro et al. (2014) also tracked the
spatial organization of tumor clones in
response to therapy. By measuring inter-
cell distances of clones with different
8q24 and chr8 CEP copy-number states,
they observed differences in the spatial
distribution of clones after therapy. In418 Cell Reports 6, February 13, 2014 ª2014most patients the tumor clones remained
intermixed within tissue regions rather
than clustering into distinct regions.
These results differ from recent studies
in kidney tumors in which multiple regions
were sampled for next-generation
sequencing (Gerlinger et al., 2012) but
are consistent with an earlier report in
breast cancer in which genomic copy-
number profiling and FISH were used to
show the intermingling of clones in
the same geographical regions (Navin
et al., 2010).
On the contrary, Almendro et al. (2014)
found strong evidence for phenotypic
clustering in response to therapy. To
better understand the spatial organization
of phenotypes in response to therapy,
they developed a mathematical simula-
tion that incorporated empirical parame-
ters, including cell proliferation rates
(Ki67). By modeling each patient, theyThe Authorsfound that the clustering of tumor cells
with similar phenotypes could not be
solely attributed to cell divisions, placing
their daughter cells in adjacent regions,
but instead must require phenotype
switching in distinct regions of the tumor.
They also modeled the effects of cell
migration, which increased the rate of
phenotype switching, and may be neces-
sary for converting the scattered migra-
tory cells back to the correct phenotype
in a distinct region of the tumor.
These studies highlight the importance
of cellular phenotypes in developing
resistance to chemotherapy and the clin-
ical value of measuring diversity to predict
complete response. Furthermore, they
illustrate the power of combining experi-
mental data with mathematical modeling
to understand complex biological pro-
cesses in cancer. However, these data
are inconsistent with a recent study in
acute myeloid leukemia that employed
next-generation sequencing to analyze
pre- and posttherapy samples (Ding
et al., 2012), showing evidence of
decreasing genetic diversity in response
to therapy as minor clones emerged
with new resistance mutations. Although
these pioneering studies have begun to
unravel the complex interplay between
genetic and phenotypic diversity in the
evolution of chemoresistance, additional
work combining both cytogenetic and
genomic tools will be needed to fully
understand this complex process, which
plagues the treatment of most human
cancers.
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